Zevra Therapeutics, Inc. (ZVRA) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
ZVRA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ZVRA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 84.5% | -4.0% | 78.2% |
| 2024 | 68.6% | -368.5% | -446.9% |
| 2023 | 89.3% | -180.6% | -167.7% |
| 2022 | 97.8% | -418.9% | -263.5% |
| 2021 | 92.8% | 27.0% | -29.9% |
Download Data
Export ZVRA earnings history in CSV or JSON format
Free sign-in required to download data
Zevra Therapeutics, Inc. (ZVRA) Earnings Overview
As of May 8, 2026, Zevra Therapeutics, Inc. (ZVRA) reported trailing twelve-month net income of $124M, reflecting +159.2% year-over-year growth. The company earned $2.06 per diluted share over the past four quarters, with a net profit margin of 78.2%.
Looking at the long-term picture, ZVRA's historical earnings data spans multiple years. The company achieved its highest annual net income of $83M in fiscal 2025, representing a new all-time high.
Zevra Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 84.5%, operating margin of -4.0%, and net margin of 78.2%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), ZVRA has outperformed on profitability metrics. Compare ZVRA vs RARE →
ZVRA Earnings vs Peers
Earnings metrics vs comparable public companies
ZVRA Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $83M | +178.9% | -$4M | $1.35 | 78.2% | -4.0% |
| 2024 | -$106M | -129.1% | -$87M | $-2.28 | -446.9% | -368.5% |
| 2023 | -$46M | -72.0% | -$50M | $-1.30 | -167.7% | -180.6% |
| 2022 | -$27M | -212.9% | -$43M | $-0.78 | -263.5% | -418.9% |
| 2021 | -$9M | +33.0% | $8M | $-2.11 | -29.9% | 27.0% |
| 2020 | -$13M | +48.0% | -$6M | $-3.21 | -96.0% | -42.2% |
| 2019 | -$25M | +56.6% | -$20M | $-13.23 | -191.0% | -158.4% |
| 2018 | -$56M | -30.1% | -$56M | $-50.39 | - | - |
| 2017 | -$43M | -162.7% | -$33M | $-47.37 | - | - |
| 2016 | -$17M | +69.8% | -$37M | $-18.10 | - | - |
See ZVRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZVRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZVRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZVRA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVRA stock.
Is ZVRA growing earnings?
ZVRA EPS is $2.06, with earnings growth accelerating to +159.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $124M.
What are ZVRA's profit margins?
Zevra Therapeutics, Inc. net margin is +78.2%, with operating margin at -4.0%. Above-average margins indicate pricing power.
How consistent are ZVRA's earnings?
ZVRA earnings data spans 2012-2025. The accelerating earnings trend is +159.2% YoY. Historical data enables comparison across business cycles.